Pfizer Reports Q2 2026 Revenue Growth Despite Significant Losses

Pfizer Inc. reported its financial results for the second quarter and first half of 2026, revealing total revenues of $15.0 billion for the quarter, a 3% increase from $14.7 billion in the same period last year. For the first six months, revenues rose to $29.5 billion, up 4% from $28.4 billion in 2025. The growth was attributed to increased sales of key products such as Eliquis, Padcev, and the Vyndaqel family, although this was partially offset by declines in COVID-19 product revenues, particularly from Comirnaty and Paxlovid. The company noted an operational revenue increase of 1% for the quarter and 2% for the first half, with foreign exchange fluctuations contributing an additional 1% to both periods.

In terms of profitability, Pfizer reported a loss from continuing operations of $653 million for the second quarter, a significant decline from the $3.0 billion profit recorded in the same quarter of 2025. This downturn was primarily driven by charges related to intangible asset impairments and legal matters, as well as increased restructuring costs. For the first half of 2026, the loss from continuing operations was $2.5 billion, down from a profit of $5.8 billion in the prior year. The effective tax rate for the second quarter was notably high at 62.4%, compared to 4.6% in the previous year, reflecting changes in the jurisdictional mix of earnings and the impact of asset impairments.

Strategically, Pfizer has been active in business development, including the acquisition of Metsera, a clinical-stage biopharmaceutical company, for approximately $8 billion. This acquisition is expected to enhance Pfizer's capabilities in treating obesity and cardiometabolic diseases. Additionally, Pfizer entered into a collaboration agreement with Innovent for the development of cancer medicines, which includes significant milestone payments and royalties. The company is also focusing on cost-saving initiatives, with a projected $6.7 billion in savings from its ongoing cost realignment program through 2029.

Operationally, Pfizer's total assets decreased to $201.1 billion as of June 28, 2026, down from $208.2 billion at the end of 2025. The company reported a reduction in cash and cash equivalents to $976 million, alongside a decrease in inventories. The workforce remained stable, with 5.7 billion shares of common stock outstanding. Looking ahead, Pfizer anticipates continued revenue growth driven by its product pipeline and strategic initiatives, despite facing challenges from patent expirations and pricing pressures in the pharmaceutical market. The company remains committed to enhancing shareholder value through dividends and potential share repurchases in the future.